Cover Image
市場調查報告書

心肌炎 : 開發中產品分析

Myocarditis - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 302498
出版日期 內容資訊 英文 34 Pages
訂單完成後即時交付
價格
Back to Top
心肌炎 : 開發中產品分析 Myocarditis - Pipeline Review, H1 2017
出版日期: 2017年03月15日 內容資訊: 英文 34 Pages
簡介

心肌炎是指心臟肌肉發炎,一般是由於到達心臟的病毒、細菌、真菌感染造成。是發病率不高的疾病。主要症狀有胸痛和心跳數急增/異常、休息時或是身體活動時的呼吸困難、伴隨腿部·腳踝·腳腫脹的體液積留、倦怠感等。主要的治療方法有利用抗生素和抗發炎劑消除腫脹,利用利尿劑排放出過剩體液等。

本報告提供全球各國治療心肌炎所用的開發中產品開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

心肌炎概要

治療藥的開發

  • 心肌炎開發中產品:概要
  • 心肌炎開發中產品:比較分析

各企業開發中的心肌炎治療藥

大學/研究機關研究中的心肌炎治療藥

開發中產品的概要

  • 初期階段的產品

心肌炎治療藥:開發中的產品一覽(各企業)

心肌炎治療藥:研究中的產品一覽(各大學/研究機關)

心肌炎治療藥的開發企業

  • CEL-SCI Corporation
  • GlaxoSmithKline Plc

心肌炎:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各分子類型

藥物簡介

  • CEL-1000
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • 自體免疫性心肌炎IL-10 活性化細胞療法
  • 自體免疫性心肌炎Flt3L標的細胞療法
  • 南美錐蟲病疫苗
  • 適合心血管障礙的α肌凝蛋白抑制劑
  • OBR-5340
  • 適合心肌炎的克沙奇病毒B3 3C蛋白分解酵素的抑制劑

暫停中的計劃

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9051IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocarditis - Pipeline Review, H1 2017, provides an overview of the Myocarditis (Cardiovascular) pipeline landscape.

Myocarditis is inflammation of the heart muscle. Myocarditis is an uncommon disorder that is usually caused by viral, bacterial, or fungal infections that reach the heart. Symptoms include chest pain, rapid or abnormal heartbeat, shortness of breath, at rest or during physical activity, fluid retention with swelling of legs, ankles and feet and fatigue. Treatment includes antibiotics, anti-inflammatory medicines to reduce swelling and diuretics to remove excess water from the body.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myocarditis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Myocarditis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocarditis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocarditis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Myocarditis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Myocarditis (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Myocarditis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Myocarditis (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Myocarditis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Myocarditis (Cardiovascular)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Myocarditis (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Myocarditis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Myocarditis - Overview
  • Myocarditis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Myocarditis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Myocarditis - Companies Involved in Therapeutics Development
    • CEL-SCI Corp
    • GlaxoSmithKline Plc
    • Swedish Orphan Biovitrum AB
  • Myocarditis - Drug Profiles
    • anakinra - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CEL-1000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target Flt3L for Autoimmune Myocarditis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • chagas disease vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OBR-5340 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Coxsackievirus B3 3C Protease for Myocarditis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VY-OZ - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Myocarditis - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Myocarditis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Myocarditis - Pipeline by CEL-SCI Corp, H1 2017
  • Myocarditis - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Myocarditis - Pipeline by Swedish Orphan Biovitrum AB, H1 2017
  • Myocarditis - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Myocarditis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top